Canine Distemper Virus Patents (Class 424/213.1)
  • Patent number: 9393298
    Abstract: The present invention discloses liquid stable bovine vaccines that comprise a live attenuated virus, in sucrose, arginine, and methionine. The present invention also discloses the manufacture of such vaccines and methods of protecting an animal by administration of such vaccines.
    Type: Grant
    Filed: March 10, 2014
    Date of Patent: July 19, 2016
    Assignee: Intervet Inc.
    Inventors: Sandhya Buchanan, Kevin O'Connell
  • Publication number: 20150140102
    Abstract: The present invention pertains to a method for producing a medicinal product comprising a biologically active protein comprising the steps of providing an aqueous composition comprising a solvent, the biologically active protein and between 20% w/w and 60% w/w of a non-polymeric sugar, freezing the composition, thereby forming at least one frozen body comprising the solvent in frozen form, putting the frozen body in a drying apparatus while being carried by a support, the support comprising one or more restraining elements that define one or more boundaries of the support, wherein at most 30% of the surface of the body is contiguous with the one or more restraining elements, reducing the pressure in the drying apparatus below atmospheric pressure, providing heat to the body in order to sublimate the frozen solvent of the body and obtain a dried body. The invention also pertains to a product obtainable by this method.
    Type: Application
    Filed: July 9, 2013
    Publication date: May 21, 2015
    Inventors: Kevin O'Connell, Sandhya Buchanan
  • Patent number: 8784843
    Abstract: The present invention relates generally to the fields of immunology and vaccine technology. More specifically, the present invention relates to stabilizers for freeze-dried live attenuated immunogenic and/or vaccine compositions, which may comprise, inter alia, canine paramyxovirus. The invention further relates to stabilized, freeze-dried live attenuated immunogenic and/or vaccine compositions of, for example, canine paramyxovirus, which may contain these stabilizers. Other aspects of the invention are described in or are obvious from the following disclosure, and are within the ambit of the invention.
    Type: Grant
    Filed: September 15, 2006
    Date of Patent: July 22, 2014
    Assignee: Merial Limited
    Inventors: Delphine Magali Belin-Poput, Noel Yves Henri Jean Genin
  • Publication number: 20140056942
    Abstract: The present invention discloses liquid stable vaccines that comprise a live attenuated virus, 10-30% sugar additive, and an amino acid. The present invention also discloses the manufacture of such vaccines and methods of protecting an animal by administration of such vaccines.
    Type: Application
    Filed: August 15, 2013
    Publication date: February 27, 2014
    Inventors: Zhisong Qiao, Kevin O'Connell
  • Patent number: 8647637
    Abstract: Immunogenic compositions and broad-spectrum vaccines containing newly identified isolates of canine distemper virus (CDV) collected from a geographic area are provided. The newly identified isolates exhibit attributes of both European wildlife lineage CDV and one or both of Arctic and American-2 lineage CDV. Therefore, the vaccines are broadly protective against infection with European wildlife lineage CDV and either Arctic lineage CDV or American-2 lineage CDV, or both Arctic and American-2 lineage CDV.
    Type: Grant
    Filed: January 29, 2010
    Date of Patent: February 11, 2014
    Assignee: The Board of Regents for Oklahoma State University
    Inventor: Sanjay Kapil
  • Publication number: 20110081378
    Abstract: Iscom particles can be used as an adjuvant for preparing of an antigenic composition which comprises live micro-organisms and/or killed micro-organisms and/or antigenic molecules. A composition may comprise at least one iscom particle and one or more live micro-organisms and/or killed micro-organisms and/or antigenic molecules. A kit can comprise at least one compartment containing at least one living organism and at least one compartment containing at least one iscom particle.
    Type: Application
    Filed: October 15, 2010
    Publication date: April 7, 2011
    Applicant: Isconova AB
    Inventors: Bror Morein, Karin Lovgren Bengtsson
  • Publication number: 20100196420
    Abstract: Immunogenic compositions and broad-spectrum vaccines containing newly identified isolates of canine distemper virus (CDV) collected from a geographic area are provided. The newly identified isolates exhibit attributes of both European wildlife lineage CDV and one or both of Arctic and American-2 lineage CDV. Therefore, the vaccines are broadly protective against infection with European wildlife lineage CDV and either Arctic lineage CDV or American-2 lineage CDV, or both Arctic and American-2 lineage CDV.
    Type: Application
    Filed: January 29, 2010
    Publication date: August 5, 2010
    Applicant: THE BOARD OF REGENTS FOR OKLAHOMA STATE UNIVERSITY
    Inventor: Sanjay Kapil
  • Publication number: 20100028379
    Abstract: This invention relates to a method of treating a dog for canine diseases comprising administering to the dog therapeutically effective amounts of a vaccine, wherein the vaccine comprises viral antigens, a bacterin, or both, and wherein the vaccine is administered subcutaneously or orally according to the schedules provided herein.
    Type: Application
    Filed: November 23, 2007
    Publication date: February 4, 2010
    Applicants: PFIZER, INC, PFIZER PRODUCTS INC.
    Inventors: Cassius M. Tucker, John David Haworth
  • Patent number: 7572454
    Abstract: The present invention provides T helper cell epitopes and compositions for use in inducing an immune response comprising at least one of these epitopes.
    Type: Grant
    Filed: June 19, 2007
    Date of Patent: August 11, 2009
    Assignees: CSL Limited, The University of Melbourne
    Inventors: David Charles Jackson, Souravi Ghosh, John Walker
  • Publication number: 20080286295
    Abstract: The present invention includes a method to determine the immune status of an animal that includes the steps of (a) contacting a biological specimen of the animal with a recombinant infectious agent antigen that is specific for detecting an antibody selective for that infectious agent, under conditions suitable for formation of a complex between the recombinant antigen and the antibody and (b) detecting the presence or absence of the complex, wherein presence or absence of a complex is indicative of the immune status of the animal. Preferably such a method indicates whether the animal should be vaccinated. The present invention also includes an assay comprising (a) a recombinant infectious agent antigen that is specific for detecting an antibody selective for that infectious agent; and (b) a means to detect an antibody that selectively binds to the recombinant antigen.
    Type: Application
    Filed: May 29, 2008
    Publication date: November 20, 2008
    Inventors: Wayne A. Jensen, Michael R. Lappin, David K. Rosen, Janet S. Andrews
  • Patent number: 7241448
    Abstract: The present invention provides T helper cell epitopes and compositions for use in inducing an immune response comprising at least one of these epitopes. The epitopes are contained within a peptide sequence selected from the group consisting of EPINQALTLMTKNVKPL (SEQ ID NO: 12); FAGVVLAGVALGVATAA (SEQ ID NO: 13); NLNAQAIQSLRTSLEQS (SEQ ID NO: 17) and TELLSIFGPSLRDPISA (SEQ ID NO: 20).
    Type: Grant
    Filed: May 4, 2006
    Date of Patent: July 10, 2007
    Assignees: CSI Limited, The University of Melbourne
    Inventors: David Charles Jackson, Souravi Ghosh, John Walker
  • Patent number: 7208163
    Abstract: It was found that a mutation of an amino acid at a specific position in the P protein of a morbillivirus gives a temperature-sensitivity character to a virus. By introducing this mutation, a virus to which a temperature-sensitivity character has been introduced can be produced. According to this invention, attenuated viruses useful in the preparation of vaccines can be easily produced.
    Type: Grant
    Filed: October 18, 2000
    Date of Patent: April 24, 2007
    Assignee: The Kitasato Institute
    Inventors: Katsuhiro Komase, Noriko Suzuki, Tetsuo Nakayama, Chikara Aizawa
  • Patent number: 7097844
    Abstract: The present invention provides T helper cell epitopes and compositions for use in inducing an immune response comprising at least one of these epitopes. The epitopes are contained within a peptide sequence selected from the group consisting of PRTSDRPVSYTMNRTRS (SEQ ID NO: 4); TRSRKQTSHRLKNIPVH (SEQ ID NO: 5); SHQYLVIKLIPNASLIE (SEQ ID NO: 6); and SPDKLLTFIASDTCPLV (SEQ ID NO: 25).
    Type: Grant
    Filed: November 13, 2003
    Date of Patent: August 29, 2006
    Assignees: CSL Limited, The University of Melbourne, Commonwealth Scientific and Industrial Research Organisation, The Council of Queensland Institute of Medical Research, Walter and Eliza Hall Institute of Medical Research
    Inventors: David Charles Jackson, Souravi Ghosh, John Walker
  • Patent number: 7037507
    Abstract: The present invention provides T helper cell epitopes and compositions for use in inducing an immune response comprising at least one of these epitopes. The epitopes are contained within a peptide sequence selected from the group consisting of SSKTQTHTQQDRPPQPS (SEQ ID NO: 1); QPSTELEETRTSRARHS (SEQ ID NO: 2); QSLRTSLEQSNKAIEEI (SEQ ID NO: 18); and DESSCVFVSESAICSQN (SEQ ID NO: 23).
    Type: Grant
    Filed: September 8, 2004
    Date of Patent: May 2, 2006
    Assignees: CSL Limited, The University of Melbourne
    Inventors: David Charles Jackson, Souravi Ghosh, John Walker
  • Patent number: 6875436
    Abstract: It was found that a mutation of an amino acid at a specific position in the F protein of a morbillivirus induces a reduction in the cell-fusion ability. By introducing this mutation, a virus having a reduced cell-fusion ability can be produced. Thus, attenuated viruses useful in the preparation of vaccines can be easily produced.
    Type: Grant
    Filed: October 18, 2000
    Date of Patent: April 5, 2005
    Assignee: The Kitasata Institute
    Inventors: Katsuhiro Komase, Tetsuo Nakayama, Chikara Aizawa
  • Patent number: 6685947
    Abstract: The present invention provides T helper cells epitopes and compositions for use in inducing an immune response comprising at least one of these epitopes.
    Type: Grant
    Filed: March 22, 2002
    Date of Patent: February 3, 2004
    Assignees: CSL Limited, The University of Melbourne, Commonwealth Scientific and Industrial Research Organisation, The Council of Queensland Institute of Medical Research, Walter and Eliza Hall Institute of Medical Research
    Inventors: David Charles Jackson, Souravi Ghosh, John Walker
  • Patent number: 6656719
    Abstract: Defined serum-free, low protein media (LPKM), that supports 1) Vero cell growth for up to 20 passages, 2) Vero cell growth on microcarriers and 3) rotavirus production is provided. Maximum cell densities attained are 60-100% of that in serum-containing medium; the doubling time is equal to that for cells in serum containing medium. Rotavirus titers achieved in LPKM-1 are 50-100% of the serum-containing process. Finally, since LPKM-1 contains no animal-sourced proteins, the problems associated with the serum-containing rotavirus production process (i.e. lengthy wash steps before infection, potential introduction of adventitious agents and lot-to-lot variability) can be avoided; while maintaining nearly equivalent product titers.
    Type: Grant
    Filed: October 21, 1998
    Date of Patent: December 2, 2003
    Assignee: Merck & Co., Inc.
    Inventors: Sandra L. Gould, David K. Robinson, Daniel J. Distefano, T. Craig Seamans
  • Publication number: 20030206925
    Abstract: Modified Morbilliviruses having at least one mutation in the region corresponding to amino acids 112-134 of the measles virus V protein are described, wherein one or both of amino acids 113 or 114 is mutated. Such modified Morbilliviruses exhibit reduced repression of gene expression. Additional mutations or deletions in other regions of the genome may be included, including in the carboxy-terminal region.
    Type: Application
    Filed: December 16, 2002
    Publication date: November 6, 2003
    Inventor: Christopher L. Parks
  • Publication number: 20030190330
    Abstract: The present invention provides a vaccine against canine distemper and leishmaniasis by constructing a recombinant canine distemper virus containing a gene encoding a protein associated with protection against Leishmania protozoa infection inserted into the canine distemper virus vector.
    Type: Application
    Filed: October 4, 2002
    Publication date: October 9, 2003
    Applicant: NIPPON BIOLOGICALS, INC.
    Inventors: Chieko Kai, Ryuichi Miura, Yoshitsugu Matsumoto
  • Publication number: 20030082204
    Abstract: Attenuated recombinant viruses containing DNA coding for a canine distemper virus antigen or measles M or N antigen, as well as methods and compositions employing the viruses, are disclosed and claimed. The recombinant viruses can be NYVAC or ALVAC recombinant viruses. The DNA can code for at least one of: canine distemper virus fusion protein, canine distemper virus hemagglutinin glycoprotein, canine distemper nucleocaspid portein, canine distemper matrix protein, measles virus nucleocaspid protein, and measles virus matrix protein. The recombinant viruses and gene products therefrom are useful for eliciting protection against canine distemper virus and/or measles virus, and, the gene products and antibodies elicited thereby are useful in assays. Additionally, DNA from the recombinants is used for probes or for generating PCR primers.
    Type: Application
    Filed: September 13, 2001
    Publication date: May 1, 2003
    Applicant: Aventis Pasteur.
    Inventors: Enzo Paoletti, James Tartaglia, Jill Taylor, Russell Gettig
  • Publication number: 20020123041
    Abstract: The present invention relates to a treatment for animals having canine distemper by administering a composition comprising an attenuated canine distemper virus a sub-vaccine virus level effective to alleviate symptoms canine distemper. The invention also provides a treatment for animals having canine distemper by administering a composition comprising an attenuated canine measles virus a sub-vaccine virus level effective to alleviate symptoms canine distemper.
    Type: Application
    Filed: April 30, 2002
    Publication date: September 5, 2002
    Inventor: John McMichael
  • Patent number: 6383741
    Abstract: The present invention relates to a treatment for animals having canine distemper by administering a composition comprising an attenuated canine distemper virus a sub-vaccine virus level effective to alleviate symptoms canine distemper. The invention also provides a treatment for animals having canine distemper by administering a composition comprising an attenuated canine measles virus a sub-vaccine virus level effective to alleviate symptoms canine distemper.
    Type: Grant
    Filed: December 22, 2000
    Date of Patent: May 7, 2002
    Assignee: Milkhaus Laboratory, Inc.
    Inventor: John McMichael
  • Patent number: 6309647
    Abstract: Attenuated recombinant viruses containing DNA coding for a canine distemper virus antigen or measles M or N antigen, as well as methods and compositions employing the viruses, are disclosed and claimed. The recombinant viruses can be NYVAC or ALVAC recombinant viruses. The DNA can code for at least one of: canine distemper virus fusion protein, canine distemper virus hemagglutinin glycoprotein, canine distemper nucleocaspid protein, canine distemper matrix protein, measles virus nucleocaspid protein, and measles virus matrix protein. The recombinant viruses and gene products therefrom are useful for eliciting protection against canine distemper virus and/or measles virus, and, the gene products and antibodies elicited thereby are useful in assays. Additionally, DNA from the recombinants is used for probes or for generating PCR primers.
    Type: Grant
    Filed: July 15, 1999
    Date of Patent: October 30, 2001
    Assignee: Aventis Pasteur
    Inventors: Enzo Paoletti, James Tartaglia, Jill Taylor, Russell Gettig
  • Publication number: 20010031267
    Abstract: The present invention relates to a treatment for animals having canine distemper by administering a composition comprising an attenuated canine distemper virus a sub-vaccine virus level effective to alleviate symptoms canine distemper. The invention also provides a treatment for animals having canine distemper by administering a composition comprising an attenuated canine measles virus a sub-vaccine virus level effective to alleviate symptoms canine distemper.
    Type: Application
    Filed: December 22, 2000
    Publication date: October 18, 2001
    Inventor: John McMichael